Outcome of Board Meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Evexia Lifecare's board approved unaudited financial results for Q3 and 9M FY26 ended Dec 31, 2025. Standalone revenue from operations rose to ₹2,459.92 lakhs in Q3 (vs ₹2,157.97 lakhs YoY) and ₹7,028.54 lakhs for 9M (vs ₹6,870.76 lakhs YoY). Standalone Q3 PAT doubled to ₹40.73 lakhs (vs ₹19.23 lakhs YoY), with 9M PAT at ₹131.58 lakhs (vs ₹117.80 lakhs). On a consolidated basis, Q3 revenue was ₹2,524.38 lakhs and 9M revenue ₹7,306.39 lakhs, with Q3 PAT of ₹29.19 lakhs and 9M PAT of ₹130.28 lakhs. The statutory auditor issued an unmodified limited review conclusion for both standalone and consolidated results, though the consolidated report carries an Emphasis of Matter noting that subsidiary financials were consolidated based on unaudited statements.
Marginal revenue growth but strong quarterly profit improvement signals better operational efficiency. The Emphasis of Matter on unaudited subsidiary numbers is a mild governance flag for retail investors tracking the consolidated picture.